Mullard, Asher

Targeted protein degraders crowd into the clinic

Mullard, A. (2021) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 409

First targeted protein degrader hits the clinic

Mullard, A. (2019) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 146

Gene therapy community grapples with toxicity issues, as pipeline matures

Mullard, A. (2021) · Nature Reviews Drug Discovery

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 112

FDA approves first BCMA-targeted CAR-T cell therapy

Mullard, A. (2021) · Nature Reviews Drug Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 81

FDA approves second BCMA-targeted CAR-T cell therapy

Mullard, A. (2022) · Nature Reviews Drug Discovery

CAR-T cell therapy researchProtein Degradation and Inhibitors

Cited by 68

Second anticancer CAR T therapy receives FDA approval

Mullard, A. (2017) · Nature Reviews Drug Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 34

Oncologists tap the microbiome in bid to improve immunotherapy outcomes

Mullard, A. (2018) · Nature Reviews Drug Discovery

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 23

FDA approves second anti-amyloid antibody for Alzheimer disease

Mullard, A. (2023) · Nature Reviews Drug Discovery

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 19

FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder

Mullard, A. (2023) · Nature Reviews Drug Discovery

Maternal Mental Health During Pregnancy and PostpartumTreatment of Major Depression

Cited by 14

Tezepelumab prepares to enter the asthma antibody fray

Mullard, A. (2021) · Nature Reviews Drug Discovery

Asthma and respiratory diseasesAllergic Rhinitis and Sensitization

Cited by 9